Sökning: id:"swepub:oai:DiVA.org:uu-139475" >
Dabigatran and Warf...
Dabigatran and Warfarin in Vitamin K Antagonist-Naive and -Experienced Cohorts With Atrial Fibrillation
-
Ezekowitz, Michael D. (författare)
-
- Wallentin, Lars (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Uppsala kliniska forskningscentrum (UCR)
-
Connolly, Stuart J. (författare)
-
visa fler...
-
Parekh, Amit (författare)
-
Chernick, Michael R. (författare)
-
Pogue, Janice (författare)
-
Aikens, Timothy H. (författare)
-
Yang, Sean (författare)
-
Reilly, Paul A. (författare)
-
Lip, Gregory Y. H. (författare)
-
Yusuf, Salim (författare)
-
visa färre...
-
(creator_code:org_t)
- 2010
- 2010
- Engelska.
-
Ingår i: Circulation. - 0009-7322 .- 1524-4539. ; 122:22, s. 2246-2253
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background-The comparison of anticoagulants dabigatran and warfarin might be most equitable in vitamin K antagonist (VKA)-naive patients. Methods and Results-Warfarin and 2 doses of dabigatran-110 mg BID (D110) and 150 mg BID (D150)-were compared in a balanced population of VKA-naive (<= 62 days of lifetime VKA exposure, with 33% never prescribed a VKA) and VKA-experienced patients with atrial fibrillation (n=18 113). For VKA-naive and -experienced patients assigned warfarin, the time in therapeutic range (international normalized ratio 2.0 to 3.0) was 62% and 67%, respectively, and 61% and 66% for those never and ever prescribed a VKA. In VKA-naive patients, stroke and systemic embolism rates were 1.57%, 1.07%, and 1.69% per year for D110, D150, and warfarin, respectively. D110 was similar to warfarin (P=0.65); D150 was superior (P=0.005). Major bleeding rates were 3.11%, 3.34%, and 3.57% per year, respectively. D110 and D150 were similar to warfarin (P=0.19 and P=0.55). Intracranial bleeding rates were 0.19%, 0.33%, and 0.73% per year, respectively. D110 and D150 were lower than warfarin (P<0.001 and P=0.005). In VKA-experienced patients, stroke and systemic embolism rates were 1.51%, 1.15%, and 1.74% per year for D110, D150, and warfarin, respectively. D110 was similar to warfarin (P=0.32); D150 was superior (P=0.007). Major bleeding rates were 2.66%, 3.30%, and 3.57% per year, respectively. D110 was lower than warfarin (P=0.003); D150 was similar (P=0.41). Intracranial bleeding rates were 0.26%, 0.32%, and 0.79% per year, respectively. D110 and D150 were lower than warfarin (P<0.001 for both). Results were similar for patients never on a VKA. Conclusions-Previous VKA exposure does not influence the benefits of dabigatran at either dose compared with warfarin.
Nyckelord
- anticoagulants
- arrhythmia
- atrial fibrillation
- stroke
- prevention
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Ezekowitz, Micha ...
-
Wallentin, Lars
-
Connolly, Stuart ...
-
Parekh, Amit
-
Chernick, Michae ...
-
Pogue, Janice
-
visa fler...
-
Aikens, Timothy ...
-
Yang, Sean
-
Reilly, Paul A.
-
Lip, Gregory Y. ...
-
Yusuf, Salim
-
visa färre...
- Artiklar i publikationen
-
Circulation
- Av lärosätet
-
Uppsala universitet